Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Receptos
Biotech
Gossamer nets $230M to test candidates against unnamed targets
Gossamer Bio netted $230 million in series B, following its $100 million launch in January, to fund immunotherapy trials against undisclosed targets.
Conor Hale
Jul 23, 2018 2:47pm
Celgene executive blames Receptos for ozanimod filing fail
Jun 13, 2018 9:28am
J.P. Morgan kicks off with a deal as Celgene pays $1.1B for Impact
Jan 8, 2018 3:42am
Celgene touts ozanimod MS data, but disability benefit weak over rival drug
May 22, 2017 8:43am
Celgene’s big hope ozanimod lowers pMS score in long-term ulcerative colitis
Oct 17, 2016 8:00am
